Mangalam Drugs and Organics
Mangalam Drugs And Organics Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Mangalam Drugs and Organics
Start SIPMangalam Drugs And Organics Investment Rating
-
Master Rating:
-
Mangalam Drugs & Orgs. has an operating revenue of Rs. 372.25 Cr. on a trailing 12-month basis. An annual revenue de-growth of -17% needs improvement, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 17 which is a POOR score indicating inconsistency in earnings, a RS Rating of 13 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 90 | 63 | 108 | 109 | 120 |
| Operating Expenses Qtr Cr | 91 | 57 | 100 | 99 | 111 |
| Operating Profit Qtr Cr | 0 | 6 | 8 | 10 | 10 |
| Depreciation Qtr Cr | 3 | 3 | 3 | 3 | 3 |
| Interest Qtr Cr | 3 | 3 | 3 | 4 | 3 |
| Tax Qtr Cr | -1 | 0 | 1 | 1 | -2 |
| Net Profit Qtr Cr | -4 | 0 | 2 | 3 | 7 |
Mangalam Drugs And Organics Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 1
- Bearish Moving Average
- ___
- 15
- 20 Day
- ₹107.71
- 50 Day
- ₹110.16
- 100 Day
- ₹114.73
- 200 Day
- ₹121.43
- 20 Day
- ₹108.42
- 50 Day
- ₹109.34
- 100 Day
- ₹113.01
- 200 Day
- ₹127.55
Mangalam Drugs And Organics Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹105.7 |
| Second Resistance | ₹107.75 |
| Third Resistance | ₹109.1 |
| RSI | 36.56 |
| MFI | 19.49 |
| MACD Single Line | -1.4 |
| MACD | -1.85 |
| Support | |
|---|---|
| First Resistance | ₹102.3 |
| Second Resistance | ₹100.95 |
| Third Resistance | ₹98.9 |
Mangalam Drugs And Organics Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 58,665 | 2,665,151 | 45.43 |
| Week | 61,395 | 2,900,895 | 47.25 |
| 1 Month | 51,104 | 2,282,309 | 44.66 |
| 6 Month | 47,502 | 1,805,076 | 38 |
Mangalam Drugs And Organics Result Highlights
Mangalam Drugs and Organics Synopsis
NSE-Medical-Generic Drugs
Mangalam Drugs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 372.25 Cr. and Equity Capital is Rs. 15.83 Cr. for the Year ended 31/03/2023. Mangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1972PLC116413 and registration number is 116413.| Market Cap | 167 |
| Sales | 372 |
| Shares in Float | 0.79 |
| No of funds | 4 |
| Yield | 0.68 |
| Book Value | 1.08 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | 12 |
| Alpha | -0.14 |
| Beta | 0.51 |
Mangalam Drugs and Organics
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 50.32% | 50.32% | 50.42% | 50.42% |
| Foreign Portfolio Investors | 0.1% | 0.1% | 0.1% | 0.1% |
| Financial Institutions/ Banks | 0.01% | |||
| Individual Investors | 44.22% | 44.27% | 44.13% | 44.18% |
| Others | 5.36% | 5.31% | 5.35% | 5.29% |
Mangalam Drugs and Organics Management
| Name | Designation |
|---|---|
| Mr. Govardhan M Dhoot | Chairman & Managing Director |
| Mr. Brijmohan M Dhoot | Whole Time Director |
| Mr. Rakesh K Milwani | Non Exe.Non Ind.Director |
| Mr. Rukmesh P Dhandhania | Independent Director |
| Mrs. Nidhi S Mundada | Independent Director |
| Mr. Praveen Saxena | Independent Director |
Mangalam Drugs And Organics Forecast
Price Estimates
Mangalam Drugs And Organics Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-30 | Audited Results | |
| 2023-02-13 | Quarterly Results | |
| 2022-11-11 | Quarterly Results | |
| 2022-08-05 | Quarterly Results | |
| 2022-05-26 | Audited & Quarterly Results |
Mangalam Drugs and Organics FAQs
What is Share Price of Mangalam Drugs and Organics ?
Mangalam Drugs and Organics share price is ₹105 As on 05 June, 2023 | 10:48
What is the Market Cap of Mangalam Drugs and Organics ?
The Market Cap of Mangalam Drugs and Organics is ₹167.6 Cr As on 05 June, 2023 | 10:48
What is the P/E ratio of Mangalam Drugs and Organics ?
The P/E ratio of Mangalam Drugs and Organics is 132 As on 05 June, 2023 | 10:48
What is the PB ratio of Mangalam Drugs and Organics ?
The PB ratio of Mangalam Drugs and Organics is 1.1 As on 05 June, 2023 | 10:48